Medical Bulletin 28/December/2021
Here are top Medical stories of the day
5-SENSE score may help identify epilepsy patients who will not benefit from invasive EEG
A team of researchers in a new study published in JAMA Neurology have developed and validated a tool that can be helpful for doctors in determining epilepsy patients who will not benefit from invasive stereoelectroencephalography (SEEG). This in turn will reduce the unnecessary invasive diagnostic burden on patients and also the overutilization of limited health care resources.
The researchers wrote, "high specificity in score development and validation confirms that the 5-SENSE score may predict patients where SEEG is unlikely to identify a focal seizure-onset zone."
For more details, check out the full story on the link below:
5-SENSE Score May Help Identify Epilepsy Patients Who Will Not Benefit From Invasive EEG: JAMA
Unilateral Palatally displaced canines may not delay tooth formation
Unilateral Palatally displaced canines (PDC) do not delay delay tooth formation and affect dental developmental age, according to a new study.
The study has been published in the American Journal of Orthodontics and Dentofacial Orthopedics.
For more details, check out the full story on the link below:
Ranitidine, a competitive antagonist of histamine-2 receptors, is used widely for the treatment of peptic ulcer disease and mild to moderate reflux esophagitis. Due to the changing lifestyle with increasing sedentary habits and poor dietary choices, there is an increasing prevalence of increased gastric acid secretion and hence the increased use of antacids including ranitidine.
Amid the safety concerns for the use of ranitidine, a recent study has found the antacid to be safe to use including in children, pregnant women, and the elderly. In the review published in the Journal of Indian Medical Association, the researchers described ranitidine to be well tolerated with rare adverse and serious adverse events related to its use.
For more details, check out the full story on the link below:
Urotronic, Inc., a Minnesota based medical device company, has announced that the U.S. Food and Drug Administration (FDA) has approved the Optilume Urethral Drug Coated Balloon for use in male urethral strictures. Optilume was granted CE mark approval for use in urethral strictures in 2020.
A urethral stricture is a scar in or around the urethra that can restrict the flow of urine from the bladder and can result in a painful, frustrating slowing of the urinary stream. Strictures can be caused by infections, trauma, and other medical procedures that injure the lining of the urethra and can significantly impact patients' quality of life. If left untreated, strictures can lead to serious complications, including bladder and kidney damage, infections, and poor ejaculation in men. Multiple endoscopic treatments of the same stricture are proven to lead to progressively worsening outcomes, recurrence, and retreatment
For more details, check out the full story on the link below:
FDA Approves Optilume Urethral Drug Coated Balloon For Urethral Strictures
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.